Drug · CHEMBL669
CYCLOBENZAPRINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CYCLOBENZAPRINE. Drugs and targets, record CHEMBL669. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL669
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3356 |
| HTR2C | 5-hydroxytryptamine receptor 2C | Serotonin 2c (5-HT2c) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3358 |
Source ChEMBL
Diseases10
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
Source Open Targets
Trials41
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 8 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02436096 | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia | Phase 3 | 519 | 2025-02-07 | TNX-102 SL | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT04508621 | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | Phase 3 | 514 | 2022-12-02 | tnx-102 sl | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT04172831 | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | Phase 3 | 503 | 2022-08-08 | cyclobenzaprine | Its name | ClinicalTrials.gov |
| NCT05273749 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia | Phase 3 | 457 | 2024-12-20 | cyclobenzaprine | Its name | ClinicalTrials.gov |
| NCT02589275 | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients | Phase 3 | 375 | 2024-12-11 | TNX-102 SL | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT03062540 | Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD | Phase 3 | 358 | 2024-05-22 | cyclobenzaprine | Its name | ClinicalTrials.gov |
| NCT01587274 | A Randomized Study of Three Medication Regimens for Acute Low Back Pain | Phase 4 | 323 | 2018-07-31 | cyclobenzaprine | Its name | ClinicalTrials.gov |
| NCT02277704 | Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions | Phase 2 | 245 | 2024-06-20 | cyclobenzaprine | Its name | ClinicalTrials.gov |
| NCT01903265 | BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) | Phase 2/3 | 205 | 2016-12-23 | cyclobenzaprine | Its name | ClinicalTrials.gov |
| NCT03841773 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD | Phase 3 | 192 | 2025-02-06 | cyclobenzaprine | Its name | ClinicalTrials.gov |
1 to 10 of 41
See all 41 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 248 | 0 of 255 | 503 | NCT04172831 | Trial comparisons |
| TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet: Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of Very Much Improved or Much Improved | 93 of 248 | 75 of 255 | 503 | NCT04172831 | Trial comparisons |
| TNX-102 SL Tablets, 5.6 mg vs Placebo SL Tablet: serious adverse events | 2 of 248 | 5 of 255 | 503 | NCT04172831 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 231 | 0 of 226 | 457 | NCT05273749 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events | 2 of 231 | 3 of 226 | 457 | NCT05273749 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of Very Much Improved or Much Improved at the Week 14 Endpoint | 66 of 231 | 34 of 225 | 456 | NCT05273749 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 179 | 0 of 179 | 358 | NCT03062540 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events | 3 of 175 | 5 of 176 | 351 | NCT03062540 | Trial comparisons |
| TNX-102 SL 2.8 mg Tablets vs Placebo: serious adverse events | 0 of 103 | 1 of 101 | 204 | NCT01903265 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 99 | 0 of 93 | 192 | NCT03841773 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials4
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Choice Reaction Time | 1 | 0 | ConductCognition |
| Gradual-Onset Continuous Performance Task | 1 | 0 | ConductCognition |
| Psychomotor Vigilance Task | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL669
GET https://conductscience.org/api/drugs/v1/CHEMBL669/trials?page=2